Personalized peptide research is advancing rapidly. New tools in genomics, proteomics, and AI-assisted protocol design are making it possible to match compounds to individual biological profiles with unprecedented precision.
Ending a research peptide protocol requires as much planning as starting one. This guide covers when and how to taper, what to document, and how to define a clean research endpoint.
Peptide cycling prevents receptor desensitization, preserves hormonal feedback loops, and maintains long-term research validity. This guide covers recommended cycle lengths by peptide category, off-cycle duration, signs of desensitization, and which blood markers to track.
Research peptide regulations vary dramatically by country. This guide maps the regulatory landscape across the US, UK, EU, Australia, and Canada so researchers know what they are working within.
The peptide industry is about to change more in 12 months than it has in the last decade. Here’s what FDA reclassification means for quality, access, pricing, and the people who’ve been in this space all along.
Switching research protocols between peptide compounds requires careful planning. This guide covers washout periods, baseline documentation, and how to structure a clean transition.
The ‘Research Use Only’ label is not just fine print. This article explains what it means legally, what it does not mean, and what researchers need to know about buying and using RUO compounds.
14 of 19 restricted peptides are being reclassified in 2026. Here’s every peptide on the list, what each one is known for, the confirmed FDA timeline, and what Category 1 status actually means.
Having research peptides seized by customs is frustrating but not always final. Here is how to navigate the process, file a petition, and work with your vendor to resolve the situation.
NorthPeptide’s 2026 catalog brings new additions, restocked staples, and expanded support for GLP-1 and longevity research. Here is what researchers need to know.
